In the original article, there were mistakes in Table 2 as published. We collected data with reference to both the conference abstract version and the full-text published version of the TRANSCEND NHL 001 trial conducted by Abramson et al. (1, 2); in Table 2 , we showed the data from the conference abstract version, which should be changed to the full-text version. The rest of the paper, including the meta-analysis and the systematic review section, was run with data from the full-text version of the TRANSCEND NHL 001 trial and is therefore unaffected. In addition, two footnotes were ignored in Table 2 . The corrected Table 2 appears below.
Table 2.
Characteristics of included studies.
| First Author | Year | No. | Median age (range)-yr | Histological type | CAR-T type | Efficacy evaluation | Scale | Toxicity evaluation (grade≥3) | Scale (CRS/ICANS) | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
| Schuster | 2018 | 111 | 56 (22–76) | DLBCL | tisa-cel | CR: 37/93 PR: 11/93 |
Lugano | CRS: 24/111 ICANS: 13/111 |
Penn/CTCAE 4.03, MDRA 20.1 | 17 |
| Schubert | 2020 | 21 | 52 (20-68) | 16 DLBCL, 3 PMBCL, 1 DHL, 1 tFL | axi-cel | CR: 9/21 PR: 10/21 |
Lugano | CRS: 0/21 ICANS: 6/21 |
ASTCT/ASTCT | 22 |
| Pinnix | 2020 | 124 | 60 (18-85) | 95 DLBCL, 20 tFL, 9 PMBCL | axi-cel | CR: 60/124 PR: 36/124 |
Lugano | CRS: 11/124 ICANS: 49/124 |
ASTCT, CARTOX/ASTCT, CARTOX | 23 |
| Nastoupil | 2020 | 298 | 60 (21-83) | 203 DLBCL, 76 tFL, 19 PMBCL | axi-cel | CR: 175/275 PR: 50/175 |
Lugano | CRS: 19/275 ICANS: 85/275 |
CARTOX, Lee/CARTOX, CTCAE 4.03 | 24 |
| Neelapu | 2017 | 101 | 58 (23–76) | 77 DLBCL, 16 tFL, 8 PMBCL | axi-cel | CR: 55/101 PR: 28/101 |
IWGRC | CRS: 13/101 ICANS: 28/101 |
Lee/CTCAE 4.03 | 19 |
| Locke | 2017 | 7 | 46 (29-69) | DLBCL | axi-cel | CR: 4/7 PR: 1/7 |
IWGRC | CRS: 1/7 ICANS: 4/7 |
Lee/CTCAE 4.03 | 25 |
| Jain | 2019 | 4 | 56 (38-66) | DLBCL | axi-cel | CR: 2/4 PR: 1/4 |
NP | CRS: 0/4 ICANS: 0/4 |
NP/NP | 26 |
| Abbasi | 2020 | 10 | 66 (55–77) | DLBCL | axi-cel | CR: 8/10 PR: 0/10 |
NP | CRS: 1/10 ICANS: 3/10 |
ASTCT/ASTCT | 27 |
| Garfall | 2018 | 10 | 61 (48-68) | MM | tisa-cel | CR: 6/10†
PR: 2/10 |
IMWGRC | CRS: 0/10 ICANS: 0/10 |
NP/NP | 28 |
| Maude | 2018 | 75 | 11 (3-23) | ALL | tisa-cel | CR: 61/75 PR: 0/75 |
Independent scale | CRS: 35/75 ICANS: 10/75 |
Penn/CTCAE 4.03 | 29 |
| Maude | 2014 | 30 | 14 (5-60) | ALL | tisa-cel | CR: 27/30 PR: 0/30 |
Independent scale | CRS: 8/30¶
ICANS: NP |
Independent scale/NP | 30 |
| Schuster | 2017 | 28 | 58 (25-77) | 14 DLBCL 14 FL |
tisa-cel | CR: 16/28 PR: 2/28 |
1999 IWGRC | CRS: 5/28 ICANS: 3/28 |
Penn/NP | 31 |
| Frigault | 2019 | 8 | 50 (17-79) | 5 DLBCL, 2 HGBCL, 1 PMBCL | tisa-cel | CR: 2/8 PR: 2/8 |
NP | CRS: 0/8 ICANS: 0/8 |
Lee, ASTCT/Lee, ASTCT | 32 |
| Sim | 2019 | 11 | NP | 8 DLBCL, 3 tFL, | axi-cel | CR: 5/11 PR: 4/11 |
Lugano | CRS: 1/11 ICANS: 3/11 |
CTCAE 5.0/CTCAE 5.0 | 33 |
| Porter | 2015 | 14 | 66 (51-78) | CLL | tisa-cel | CR: 4/14 PR: 4/14 |
IWG on CLL RC | CRS: 7/14 ICANS: 1/14 |
Penn/CTCAE 3.0 | 34 |
| Shah | 2018 | 7 | NP | 3 DLBCL, 4 FL | tisa-cel | CR: 3/7 PR: 2/7 |
Lugano | CRS: NP ICANS: NP |
NP/NP | 35 |
| Wright | 2020 | 31 | NP | 26 DLBCL, 5 tFL | 18 axi-cel, 13 tisa-cel | CR: 11/27 PR: 3/27 |
Lugano | CRS: 6/31 ICANS: 4/31 |
Penn/NP | 36 |
| Jacobson | 2020 | 122 | 62 (21-79) | 57 DLBCL, 33 tFL, 17 HGBCL, 8 PMBCL, 5 TMZL, 2 RS | axi-cel | CR: 61/122 PR: 24/122 |
Lugano | CRS: 19/122 ICANS: 43/122 |
Lee/CTCAE 4.03 | 37 |
| Abramson | 2020 | 269 | 63 (54-70) | 215 DLBCL, 36 HGBCL, 15 PMBCL, 3 FL3B | liso-cel | CR: 136/256 PR: 50/256 |
Lugano | CRS: 6/269 ICANS: 27/269 |
Lee/CTCAE 4.03 | 16 |
| Fehse | 2019 | 10 | 56 (24-79) | 7 DLBCL, 3 PMBCL | axi-cel | CR: 2/10 PR: 5/10 |
NP | CRS: 2/10 ICANS: 1/10 |
ASTCT/ASTCT | 38 |
| Gupta | 2019 | 78 | 60+-13※ | DLBCL | 69 axi-cel, 9 tisa-cel | CR+PR: 43/78* | NP | CRS: 10/78 ICANS: 22/78 |
CTCAE 5.0, Lee/CTCAE 5.0 | 39 |
| Korell | 2020 | 25 | 54 (20-68) | 24 DLBCL, 1 PMBCL | axi-cel | CR: 9/25 PR: 10/25 |
Lugano | CRS: NP ICANS: NP |
NP/NP | 40 |
| Frey | 2019 | 35 | 34 (21-70) | ALL | tisa-cel | CR: 24/35 PR: 0/35 |
Independent scale | CRS: 25/35 ICANS: 2/35 |
Penn/CTCAE 4.03 | 41 |
| Sesques | 2020 | 61 | 59 (27-75) | 38 DLBCL, 18 PMBCL, 4 tFL, 1 TMZL | 28 axi-cel, 33 tisa-cel | CR: 28/61 PR: 9/61 |
Lugano | CRS: 5/61 ICANS: 6/61 |
ASTCT/ASTCT | 42 |
| Holtzman | 2020 | 45 | 60 (26-75) | 35 DLBCL, 3 PMBCL, 7 tFL | axi-cel | CR: 22/45 PR: NP |
NP | CRS: NP ICANS: 18/45 |
NP/CTCAE 4.03 | 43 |
| Strati | 2020 | 100 | 60 (18-85) | LBCL (Including 77 DLBCL) | axi-cel | CR: NP PR: NP |
Lugano | CRS: 9/100 ICANS:41/100 |
CARTOX/CARTOX | 44 |
| Faramand | 2020 | 75 | 63 (23-79 | 50 DLBCL, 25 Transformed Indolent lymphomas | axi-cel | CR: 36/68 PR: 29/68 |
Lugano | CRS: 12/75 ICANS: 23/75 |
ASTCT/CARTOX, ASTCT, CTCAE v4.03 | 45 |
| Kittai | 2020 | 9 | 64 (40-77) | RS | axi-cel | CR: 8/8 PR: 5/8 |
Lugano | CRS: 1/9 ICANS: 3/9 |
ASTCT/ASTCT | 46 |
| Deng | 2020 | 24 | 58 (24-74) | 16 DLBCL, 6 tFL, 2 PMBCL | axi-cel | CR: NP PR: NP |
NP | CRS: 4/24 ICANS: 12/24 |
NP/NP | 47 |
| Dean | 2020 | 96 | 64 (19-79) | 47 DLBCL, 15 HGBCL, 5 PMBCL, 29 NP | axi-cel | CR: 74/96 PR: 63/96 |
NP | CRS: 9/96 ICANS: 28/96 |
Lee/CTCAE 4.03 | 48 |
| Sermer | 2020 | 69 | 63 (19-85) | DLBCL | 47 axi-cel, 22 tisa-cel | CR: 50/69 PR: 36/69 |
Lugano | CRS: NP ICANS: NP |
NP/NP | 49 |
| Wudhikarn | 2020 | 60 | 63 (20-86) | DLBCL | 43 axi-cel, 17 tisa-cel | CR: NP PR: NP |
NP | CRS: 7/60 ICANS: 13/60 |
NP/NP | 50 |
| Rubin | 2020 | 204 | 60+-12※ | Inexact# | axi-cel | CR: NP PR: NP |
NP | CRS: NP ICANS: 51/204 |
NP/CTCAE 4.03 | 51 |
CR, complete response; PR, partial response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; DLBCL, diffuse large B cell lymphoma; FL/tFL, follicular lymphoma or transformed follicular; PMBCL, primary mediastinal B-cell lymphoma; HGBCL, high-grade B cell lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CAR-T, chimeric antigen receptor T; TMZL, transformed marginal zone lymphoma; MM, multiple myeloma; NP, not provided; ref, reference; MDRA, Medical Dictionary for Regulatory Activities, version; CTCAE, Common Terminology Criteria for Adverse Events; RS, Richter’ s syndrome; ASTCT, American Society for Transplantation and Cellular Therapy criteria; CARTOX, CAR-T-cell-therapy-associated TOXicity; IWGRC, International Working Group Response Criteria; IMWGRC, International Myeloma Working Group response criteria; IWG on CLL RC, International Workshop Group on CLL response criteria.
Independent scale: the institution used their own criteria instead of international criteria, which can be found in original text.
†Very good partial response was analyzed as complete response.
¶The statement in original text was severe CRS, but it was not clear if it was ≥ grade 3 and therefore not included for analysis.
*No separate CR and PR numbers were provided.
※Mean ± standard deviation.
#Patients with aggressive (e.g., diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma) or indolent (e.g., follicular lymphoma, marginal zone lymphoma) histologic subtype.
In the original article, the neurotoxicity result of tisa-cel in the Primary Mediastinal B Cell Lymphoma subgroup was incorrectly stated. A correction has been made to Results, Primary Mediastinal B Cell Lymphoma, Paragraph 1.
“A study on tisa-cel that included one patient with PMBCL with central nervous system (CNS) involvement indicated that the patient was showing ongoing response at day 90 and developed only grade 1 CRS and no ICANS”.
Secondly, a percentage was carelessly written incorrectly in the comparison of severe cytokine release syndrome between adult and pediatric patients with acute lymphoblastic leukemia. A correction has been made to Results, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia, Paragraph 3.
“Adult patients with ALL were more likely to develop grade ≥3 CRS than pediatric patients (71 vs 47%, respectively)”.
In addition, we carelessly wrote “tisa-cel” instead of “liso-cel” and used a wrong percentage in one place. A correction has been made to Discussion, Paragraph 5.
“In the TRANSCEND NHL 001 trial, 7% of patients received non-conforming products, two patients experienced manufacturing failure of liso-cel, and 10% of patients died before receiving liso-cel.”
In the original article, there was a mistake in the legend for Figure 8 as published. “tisa-cel” was carelessly written as “axi-cel”. The correct legend appears below.
Figure 8.
The forest plots of pooled results in patients with acute lymphoblastic leukemia. (A) The forest plot of complete response rate of tisa-cel. (B) The forest plot of severe cytokine release syndrome rate of tisa-cel. (C) The forest plot of severe immune effector cell-associated neurotoxicity syndrome rate of tisa -cel.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal Safety and Efficacy Results From Transcend NHL 001, A Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood (2019) 134(Supplement_1):241. doi: 10.1182/blood-2019-127508 [DOI] [Google Scholar]
- 2. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study. Lancet (2020) 396:839–52. doi: 10.1016/S0140-6736(20)31366-0 [DOI] [PubMed] [Google Scholar]